The Marked Chart Wire · Health
Pfizer
Fda clears Pfizer's talazoparib for prostate cancer treatment
The U.S. Food and Drug Administration approved Pfizer's TALZENNA in combination with XTANDI for specific prostate cancer patients.
The stocks in this story
Prices from Based on Mon, Oct 26 close · Opens Tue 9:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
More Health news
Moderna
Moderna chief expects melanoma shot to treat other cancers
The biotech executive stated that the current melanoma vaccine is anticipated to show efficacy against additional types of malignancy.
Keytruda
Merck's Keytruda trial hits goal in endometrial cancer
Merck reported that its Phase 3 study achieved its main objective. Keytruda alone cut the chance of disease worsening or patient mortality by 43 percent relative to standard chemotherapy for specific advanced cases.
Eikon Therapeutics
Eikon reports positive data for lung cancer therapy
Eikon Therapeutics stated that EIK1001, used with standard treatments, showed lasting results in advanced non-small cell lung cancer. The company said the side effect profile allows for outpatient care.
Lung Cancer
Hutchmed reports Safron trial results for lung cancer drug combo
Hutchmed announced that its Safron Phase III study showed a 45 percent reduction in disease progression or death risk for patients with specific lung cancer mutations when using Orpathys with Tagrisso instead of chemotherapy.
AstraZeneca ADCs
AstraZeneca plans cancer drug filing after trial results
AstraZeneca will seek approval for sonesitatug vedotin after a trial showed a 42 percent reduction in death risk for gastric cancer patients. The company projects peak annual sales of $3 billion to $5 billion for the drug.
BeOne Medicines
BeOne Medicines reports 36 percent response rate in liver cancer trial
BeOne Medicines presented ESMO data for its experimental bispecific antibody. The drug showed a 36 percent confirmed response rate in advanced liver cancer cases with a good safety profile at the Phase 3 dose.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.